Search
BioLine RX Ltd
BLRXAdd to Watchlist
3.285USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
14.29MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of BioLine RX Ltd is 8.00, ranking 167 out of 387 in the Biotechnology & Medical Research industry. The average price target is 26.00, with a high of 40.00 and a low of 12.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
17.500
Target Price
+452.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BioLine RX Ltd's expected revenue for the next quarter?
BioLine RX Ltd's expected revenue is 488.50K.
What is BioLine RX Ltd's price target?
Analysts forecast that BioLine RX Ltd's price target is USD 26.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 12.00.
How have BioLine RX LtdBLRX's recent earnings per share performed?
The market expectation was USD -0.50, while BioLine RX LtdBLRX's earnings per share (EPS) for the previous quarter was USD -0.22. EPS for the next quarter is expected at USD -0.29.
What is the analyst rating for BioLine RX Ltd?
Based on the ratings of BioLine RX Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.